Short answer
Corteva (CTVA) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $4.9B (up 11.0% year over year) with net income of $720M.
Q1 2026 key financials · XBRL
- Revenue
- $4.9B
- +11.0% YoY
- Net income
- $720M
- +10.4% YoY
- EPS (diluted)
- $1.07
- +12.6% YoY
Source: XBRL data from the Corteva (CTVA) Q1 2026 10-Q on SEC EDGAR. USD.
Corteva Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $4,905M, up 11% YoY from $4,417M, driven by 6% volume, 4% currency, and 1% price
- COGS margin 48% vs 53% YoY; operating EBITDA $1,438M vs $1,189M
- Best segment Seed: sales $3,023M, up 12%; EBITDA $1,034M, up 23%; margin up approximately 310 basis points
- Worst product line Biologicals: sales down 17% YoY to implied prior-year comparison, driven by 17% volume decline
- Shareholder returns approximately $370M; restructuring charges $92M and expected savings $115M–$125M run rate by 2027
Risk Factors
- No material changes to 2025 10-K risk factors disclosed
- Regulatory and legal exposure carried forward through indemnification liabilities to Dow and DuPont totaling $131 million
- Liquidity risk from operating cash use of $2,891 million and cash decline to $2,141 million
- Market risk from currency movements, reducing comprehensive income by $129 million through translation adjustments
- Capital-allocation risk from $627 million EIDP dividends funding Corteva repurchases and common dividends
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Corteva quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.